Biotech Acquisition & Fundraise
Thalia Therapeutics acquires Sanmirna, secures £2.75M fundraise to expand clinical pipeline.
Anonymous
Key Points
1
Sanmirna deal structure: Thalia issued 485,107,215 new shares and a £764,357 convertible loan note to the Sanmirna vendors, with the vendors’ combined holding capped at 29.9%, and AIM admission to occur on 20 July, expanding Thalia’s share capital to 1,775,720,897 shares.
2
New auditor appointed: The AGM approved all resolutions including the appointment of Gravita Audit II Limited as Thalia’s new auditor, reinforcing governance ahead of the Sanmirna integration.
3
Clinical trial update: miRisten Phase 1 remains open but patient enrolment has been temporarily paused while the current cohort progresses, with topline data expected in the first half of 2027 as the company advances toward potential Phase II planning.
4
Fundraising detail: The oversubscribed £2.75 million fundraising supports planned development milestones and strengthens the capital base ahead of portfolio integration and IND-enabling work.
Thalia Therapeutics has completed its acquisition of Sanmirna Therapeutics and closed an oversubscribed £2.75 million fundraise, pushing the AIM-listed biotech into clinical-stage territory, according to Kalkine Media. The deal adds miRisten — a microRNA therapy for acute myeloid leukemia already in Phase 1 trials — to Thalia's RNA-focused pipeline.
Shares in Thalia Therapeutics (AIM: THAT) were admitted on 20 July following shareholder approval at the AGM on 17 July, according to ADVFN. The company's share capital now stands at 1,775,720,897 shares after the deal closed.
Sanmirna Deal Reshapes Thalia's Clinical Pipeline
Thalia issued 485,107,215 new shares and a £764,357 convertible loan note to the Sanmirna vendors, according to TipRanks. The vendors' combined stake was capped at 29.9% of the enlarged share capital, a standard AIM protection for existing shareholders.
The acquisition gives Thalia three key assets: miRisten for blood cancer, the Nuvec RNA delivery platform, and a dual-targeting cardiovascular siRNA programme. Together, they create a company with both oncology and cardiovascular focus — a broader base than Thalia had before the deal.
miRisten Phase 1 Trial Paused While Current Cohort Progresses
The miRisten Phase 1 trial in acute myeloid leukemia remains open, but patient enrolment has been temporarily paused. The company is waiting for the current cohort to progress before adding new patients, according to LSE.
Topline data from the trial is expected in the first half of 2027. If results are positive, Thalia plans to move into Phase 2 planning. The company is also using the period to advance IND-enabling studies for its cardiovascular candidates.
Oversubscribed £2.75m Raise Funds Key Development Milestones
The £2.75 million fundraise was oversubscribed, signalling investor demand for Thalia's expanded strategy, according to LSE. The capital will support development milestones across the portfolio and fund IND-enabling work for the cardiovascular programme.
Thalia carries no debt but does report ongoing losses and cash burn typical of a development-stage biotech. Management said the company has enough funding in place to reach key near-term milestones. The stock has traded above key moving averages since the deal was announced, showing some positive market momentum.
AGM Clears Governance Hurdles Including New Auditor Appointment
Shareholders approved all resolutions at the 17 July AGM, including the re-election of directors and the appointment of Gravita Audit II Limited as Thalia's new auditor, according to TipRanks. The auditor change reinforces governance standards ahead of the Sanmirna integration.
The AGM approval was the final step needed to complete the Sanmirna deal and trigger AIM admission of the new shares. Celebrity Land reported that Thalia is now formally positioned as a clinical-stage RNA therapeutics company with assets spanning oncology and cardiovascular disease.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
3
Reach
13
A
AnonymousAuthor